Skip to main content

glasdegib

Generic: GLASDEGIB MALEATE·Brand: DAURISMO, Daurismo

glasdegib: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.

glasdegib evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect glasdegib to PFE; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could glasdegib → PFE affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (1)
CompanyDated record stage
PFIZER INC (PFE)
Reported 2018-11-21 · Current development: unknownSource
Approved
Clinical Trial Registry Records (1)

Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

NCT04231851Registry updated 2026-07-16·Phase 2
Active, not recruiting

Primary endpoint: Percentage of Participants With Event-Free Survival at 6 Months

Interventionalopen30 enrolledStarted 2020-02Completion 2027-064 sites · United StatesUniversity of California, Irvine
FDA Decisions1 records
Approval(PFE)FDA ↗
NDA210656Type 1 - New Molecular EntityOrphan DrugPriorityOralTablet

Frequently asked questions

Which companies have sourced relationships with glasdegib?

glasdegib has dated SEC/FDA relationship records for PFIZER INC.

How many clinical trials involve glasdegib?

BioSniper tracks 1 clinical trial involving glasdegib.

What is glasdegib's latest FDA decision?

The most recent tracked FDA decision for glasdegib is Approval, dated November 21, 2018.